Successful marketing of medical technology and pharmaceutical products depends on accurate, actionable insights that can govern every stage of the development process. Guidehouse’s proven, proprietary methodologies deliver data-driven critical thinking and analysis that can generate scientific validation that help clients invest the right amount of resources at the right time.
Through comprehensive, fact-based research and analysis, we determine the realizable market potential and inform every stage of product development, including clinical trials, fundraising, commercialization, marketing and market development investments, partnerships, acquisitions, and exits.
Our Science of Market Development methodology (pioneered by Dymedex Consulting prior to its acquisition by Guidehouse), utilizes 14 critical factors to identify, assess, and reduce market risk and promote the commercial success of ventures. This rigorous process uncovers opportunities, avoids costly pitfalls, increases value, and reduces time and investment.
Our solutions align across the client’s organization, achieve key milestones, help secure funding and develop powerful, go-to-market strategies. Our solutions include:
- Strategic Market Assessment (SMA)
- Market development, entry and launch strategy
- Clinical development strategy
- Global geographic prioritization
- Portfolio management/product planning and development
- Revenue and growth forecasting
Latest From Strategic Market Development
January 10, 2022 InsightsAre You Leveraging Key Opinion Leaders for Biopharma Market Access As Much As You Could Be?For biopharma market access teams, engaging KOLs who help structure guidelines and downstream payer polices may be a high impact but untapped resource.
October 27, 2021 InsightsPotential Pitfalls of Real-World Data AnalysisTo safeguard business, product development, and commercialization strategies, it is crucial for medical device companies to validate the integrity of third-party vendor’s data and analysis expertise.
October 14, 2021 InsightsFour Critical Considerations for Launching Digital Diagnostic ToolsCreating a digital diagnostic that is supplemental and strategic to a company’s therapeutic asset requires due diligence.
September 29, 2021 PodcastInterested in Joining the Digital Therapeutics Revolution? Here’s How
August 28, 2020 InsightsDesigning Patient Services ProgramsCasey Horton, Dana Edwards, PharmaExec.com Article
April 2, 2020 Case StudyGuidehouse Insights Define New Digital Technology Market and Align Investments for $350M OpportunityRoss Meisner & Mike Fix
February 27, 2020 InsightsHow to Successfully Mitigate Risk and Dissatisfaction in Patient Service ProgramsPublished in Pharmaceutical Executive